Clinical Trials
3 trialsNCT05186012 2024-01-23
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04210037 2022-07-12
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT04354727 2022-07-12
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Phase 1/2 Withdrawn